In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) reported that Stern Adam K has picked up 2,427,250 of common stock as of 2017-03-02.
The acquisition brings the aggregate amount owned by Stern Adam K to a total of 2,427,250 representing a 4.9% stake in the company.
For those not familiar with the company, Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus.
A glance at Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP)’s key stats reveals a current market capitalization of 461.19 Million based on 44.44 Million shares outstanding and a price at last close of $9.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-22, Cohen picked up 1,340 at a purchase price of $7.64. This brings their total holding to 4,204,562 as of the date of the filing.
On the sell side, the most recent transaction saw Burstein unload 200,000 shares at a sale price of $3.04. This brings their total holding to 3,594,846.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
